Epoch Investment Partners Inc. Buys 75,400 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Epoch Investment Partners Inc. grew its stake in shares of United Therapeutics Co. (NASDAQ:UTHRFree Report) by 54.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 213,179 shares of the biotechnology company’s stock after acquiring an additional 75,400 shares during the quarter. Epoch Investment Partners Inc. owned about 0.45% of United Therapeutics worth $46,876,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of UTHR. Norges Bank bought a new stake in shares of United Therapeutics during the fourth quarter valued at approximately $100,519,000. Comerica Bank raised its stake in shares of United Therapeutics by 2,697.2% in the third quarter. Comerica Bank now owns 156,587 shares of the biotechnology company’s stock worth $35,368,000 after purchasing an additional 150,989 shares during the last quarter. Victory Capital Management Inc. raised its stake in shares of United Therapeutics by 309.7% in the fourth quarter. Victory Capital Management Inc. now owns 134,162 shares of the biotechnology company’s stock worth $29,501,000 after purchasing an additional 101,419 shares during the last quarter. TD Asset Management Inc lifted its holdings in shares of United Therapeutics by 1,066.4% during the fourth quarter. TD Asset Management Inc now owns 82,951 shares of the biotechnology company’s stock valued at $18,240,000 after purchasing an additional 75,839 shares in the last quarter. Finally, Pacer Advisors Inc. boosted its position in shares of United Therapeutics by 27.6% during the fourth quarter. Pacer Advisors Inc. now owns 312,799 shares of the biotechnology company’s stock valued at $68,781,000 after buying an additional 67,738 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on UTHR. JPMorgan Chase & Co. upped their target price on shares of United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a research note on Tuesday, May 21st. Wells Fargo & Company raised their target price on shares of United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a report on Thursday, March 7th. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. The Goldman Sachs Group raised their price target on United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd. Finally, Wedbush reiterated an “outperform” rating and set a $308.00 price objective on shares of United Therapeutics in a research report on Thursday, February 22nd. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $309.44.

Read Our Latest Research Report on United Therapeutics

United Therapeutics Stock Performance

UTHR traded down $1.40 during midday trading on Friday, reaching $275.00. The company had a trading volume of 443,604 shares, compared to its average volume of 468,481. The business has a 50-day moving average of $253.45 and a two-hundred day moving average of $236.90. The company has a quick ratio of 3.64, a current ratio of 3.77 and a debt-to-equity ratio of 0.04. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $280.30. The company has a market cap of $12.20 billion, a P/E ratio of 13.05, a P/E/G ratio of 4.12 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHRGet Free Report) last released its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.63 by $0.54. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The company had revenue of $677.70 million during the quarter, compared to analyst estimates of $620.31 million. During the same period in the prior year, the firm posted $4.86 EPS. The firm’s quarterly revenue was up 33.7% compared to the same quarter last year. As a group, equities research analysts predict that United Therapeutics Co. will post 24.61 earnings per share for the current fiscal year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, Director Nilda Mesa sold 325 shares of the firm’s stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $237.80, for a total transaction of $77,285.00. Following the sale, the director now directly owns 5,373 shares of the company’s stock, valued at $1,277,699.40. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other United Therapeutics news, Director Nilda Mesa sold 325 shares of the company’s stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $237.80, for a total value of $77,285.00. Following the completion of the transaction, the director now directly owns 5,373 shares in the company, valued at approximately $1,277,699.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Paul A. Mahon sold 6,000 shares of the business’s stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $236.45, for a total transaction of $1,418,700.00. Following the completion of the transaction, the executive vice president now directly owns 36,710 shares in the company, valued at approximately $8,680,079.50. The disclosure for this sale can be found here. Insiders sold a total of 164,328 shares of company stock valued at $40,002,673 over the last three months. Corporate insiders own 12.50% of the company’s stock.

About United Therapeutics

(Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Read More

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHRFree Report).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.